Roche boasts of stalling lung cancer with Tecentriq/chemo combo -- but rival Merck stays out front
CHICAGO — Roche arrived at ASCO boasting a significant advance for treating frontline cases of advanced squamous non-small cell lung cancer with a combination of Tecentriq and chemo. But the advantage it offers may appear relatively marginal for patients and was quickly eclipsed by more extensive positive data from a dominant Merck.
We already learned the top-line results earlier from the pharma giant, which continues to have high hopes for the PD-L1 checkpoint inhibitor, even as it’s in danger of losing its third-place position behind Merck and Bristol-Myers Squibb to a surging AstraZeneca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.